Skip to main navigation Skip to search Skip to main content

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials

D. Thaçi*, A. Kimball, P. Foley, Y. Poulin, E. Levi, R. Chen, S. R. Feldman

*Corresponding author for this work
33   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry